FDA approves first new Alzheimer’s drug in 20 years

June is Alzheimer’s and Brain Awareness Month. Alzheimer’s Disease is a form of dementia – a syndrome characterized by deterioration in memory, thinking, behavior and ability to do everyday tasks.  

Dementia affects 50 million people worldwide with 10 million cases being diagnosed each year. Alzheimer’s Disease (AD) is the most common form of dementia making up approximately 60-70% of diagnosed cases. It is one of the major causes of disability and dependence in older people.  AD is a devastating disease for those living with the condition and their carers. It also has an enormous economic and social impact.

FDA approval sparks hope of a new era in AD treatment

Current treatments act to temporarily improve symptoms but drug companies and researchers around the world are actively searching for treatments that may slow or stop the progression AD.

This week (June 7), the FDA announced approval of Biogen’s drug aducanumab for use in slowing the progression of AD. This is the first new treatment approved in nearly two decades.

Cromos Pharma is proud to support clinical research aimed at finding new treatments and maybe one day a cure for this debilitating condition. 

Read more about brain health and how you can reduce your risk of developing AD here in our Q & A with Dr Sabina Brennan.

Cromos Pharma proudly supports the Right2hope nonprofit platform, empowering patients to explore treatment options beyond traditional clinical trials. Through an intuitive, AI-supported matching algorithm, Right2hope connects patients with the most relevant expanded access, compassionate use, and right-to-try programs.